RT Journal Article
SR Electronic
T1 Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5739
OP 5747
DO 10.21873/anticanres.15390
VO 41
IS 11
A1 YUKIKO SHIMODA
A1 TATSUYA YOSHIDA
A1 MASAYUKI SHIRASAWA
A1 TAKAAKI MIZUNO
A1 HITOMI JO
A1 YUJI MATSUMOTO
A1 YUKI SHINNO
A1 YUSUKE OKUMA
A1 YASUSHI GOTO
A1 HIDEHITO HORINOUCHI
A1 NOBORU YAMAMOTO
A1 YASUSHI YATABE
A1 YUICHIRO OHE
A1 NORIKO MOTOI
YR 2021
UL http://ar.iiarjournals.org/content/41/11/5739.abstract
AB Background/Aim: Programmed death-ligand 1 (PD-L1) expression on tumor cells is a predictive biomarker of programmed cell death 1 (PD-1) blockade therapy. This study sought to clarify predictors of the efficacy of nivolumab in non-small cell lung cancer (NSCLC) patients with PD-L1 expression-negative tumors. Patients and Methods: We retrospectively reviewed the records of advanced NSCLC patients between January 2016 and April 2019, and investigated the predictive marker of nivolumab including the status of CD8+ tumor infiltrating lymphocytes (TILs). Results: A total of 70 NSCLC patients were included. Overall response rate (ORR) and progression-free survival (PFS) were better in patients with a heavy smoking history (smoking index: SI≥600) than in those without (SI<600) [ORR: 20.6% vs. 2.8%, (p=0.02), and PFS: 2.4 months vs. 1.8 months, (p=0.04)]. A high density of CD8+ TILs was significantly associated with a heavy smoking history (p=0.04). Conlusion: Heavy smoking history (SI≥600), which was correlated with a large number of CD8+ TILs, could be a predictor of the efficacy of nivolumab in NSCLC patients with PD-L1 expression-negative tumors.